Smith Group Asset Management’s Galectin Therapeutics GALT Stock Holding History

Smith Group Asset Management’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-57,970	Closed	-$85K	–	469
2016 Q2	$85K	Buy	57,970 +23,700	+69%	+$34.8K	﹤0.01%	319
2016 Q1	$49K	Buy	34,270 +8,180	+31%	+$11K	﹤0.01%	319
2015 Q4	$43K	Buy	26,090 +4,990	+24%	+$11.4K	﹤0.01%	343
2015 Q3	$49K	Buy	21,100 +2,944	+16%	+$6.94K	﹤0.01%	285
2015 Q2	$50K	Buy	18,156 +1,522	+9%	+$4.59K	﹤0.01%	279
2015 Q1	$56K	Buy	+16,634	New	+$59.4K	﹤0.01%	327

Other funds holding GALT

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

CCM

Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Smith Group Asset Management's GALT Position: Q3 2016 in Review

Smith Group Asset Management sold out of Galectin Therapeutics (GALT) in Q3 2016, closing a stake of 57,970 shares — an estimated $85K sold.

Smith Group Asset Management first reported a position in GALT in Q1 2015 and held it in 6 quarters. The position peaked at $85K in Q2 2016. 46 funds tracked by Wall St. Rank hold GALT as of Q3 2016.

Smith Group Asset Management reported no remaining Galectin Therapeutics position as of Q3 2016 after selling out during the quarter.
Smith Group Asset Management sold 57,970 Galectin Therapeutics shares in Q3 2016, an estimated $85K.
Smith Group Asset Management first reported a position in Galectin Therapeutics in Q1 2015 and held it in 6 quarters.
Smith Group Asset Management's Galectin Therapeutics position peaked at $85K in Q2 2016.
46 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2016.

Based on Smith Group Asset Management's 13F filing for Q3 2016, filed 2 Nov 2016.